The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT04706429

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04706429
  • EudraCT 2020-002242-17
  • ISRCTN ISRCTN57145331
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04706429. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-01 (actual); primary completion 2024-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
Acronym
TEMPEST
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
Trientine
Intervention (Drug)
Placebo
Lead sponsor
Manchester University NHS Foundation Trust (class: other government)
Collaborator
National Institute for Health Research, United Kingdom (class: other government)
Collaborator
University of Manchester (class: other)
Collaborator
University of Liverpool (class: other)
Collaborator
Univar BV (class: industry)
Collaborator
University of Oxford (class: other)

Record details

Record id
cardio:ct-nct04706429
Content hash
9f346432ce1fb180d5aaf2cfd8558f1b426ce11bffe01200b5d14b0e0eefee18